242 related articles for article (PubMed ID: 17343760)
1. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes.
Humpert PM; Djuric Z; Kopf S; Rudofsky G; Morcos M; Nawroth PP; Bierhaus A
Cardiovasc Diabetol; 2007 Mar; 6():9. PubMed ID: 17343760
[TBL] [Abstract][Full Text] [Related]
2. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
[TBL] [Abstract][Full Text] [Related]
3. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Umayahara Y; Kosugi K; Yamasaki Y
Atherosclerosis; 2009 May; 204(1):288-92. PubMed ID: 18926539
[TBL] [Abstract][Full Text] [Related]
4. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Yamasaki Y
Diab Vasc Dis Res; 2008 Sep; 5(3):190-7. PubMed ID: 18777492
[TBL] [Abstract][Full Text] [Related]
5. Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness.
Choi KM; Yoo HJ; Kim HY; Lee KW; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH
Int J Cardiol; 2009 Feb; 132(1):96-101. PubMed ID: 18190981
[TBL] [Abstract][Full Text] [Related]
6. Elevated endogenous secretory receptor for advanced glycation end products (esRAGE) levels are associated with circulating soluble RAGE levels in diabetic children.
Saito R; Araki S; Yamamoto Y; Kusuhara K
J Pediatr Endocrinol Metab; 2017 Jan; 30(1):63-69. PubMed ID: 27941172
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
8. Correlation of the plasma levels of soluble RAGE and endogenous secretory RAGE with oxidative stress in pre-diabetic patients.
Huang M; Que Y; Shen X
J Diabetes Complications; 2015 Apr; 29(3):422-6. PubMed ID: 25659638
[TBL] [Abstract][Full Text] [Related]
9. Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography.
Yang SJ; Kim S; Hwang SY; Kim TN; Choi HY; Yoo HJ; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
Atherosclerosis; 2012 Feb; 220(2):402-6. PubMed ID: 22137663
[TBL] [Abstract][Full Text] [Related]
10. sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes.
Humpert PM; Papadopoulos G; Schaefer K; Djuric Z; Konrade I; Morcos M; Nawroth PP; Bierhaus A
Horm Metab Res; 2007 Dec; 39(12):899-902. PubMed ID: 18046662
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.
Tan KCB; Chow WS; Tso AWK; Xu A; Tse HF; Hoo RLC; Betteridge DJ; Lam KSL
Diabetologia; 2007 Sep; 50(9):1819-1825. PubMed ID: 17639302
[TBL] [Abstract][Full Text] [Related]
12. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
[TBL] [Abstract][Full Text] [Related]
13. The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity.
Brix JM; Höllerl F; Kopp HP; Schernthaner GH; Schernthaner G
Int J Obes (Lond); 2012 Nov; 36(11):1412-7. PubMed ID: 22828946
[TBL] [Abstract][Full Text] [Related]
14. Total soluble and endogenous secretory receptor for advanced glycation endproducts (RAGE) in IBD.
Meijer B; Hoskin T; Ashcroft A; Burgess L; Keenan JI; Falvey J; Gearry RB; Day AS
J Crohns Colitis; 2014 Jun; 8(6):513-20. PubMed ID: 24291021
[TBL] [Abstract][Full Text] [Related]
15. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
Nishizawa Y; Koyama H
J Ren Nutr; 2008 Jan; 18(1):76-82. PubMed ID: 18089449
[TBL] [Abstract][Full Text] [Related]
16. Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients.
Piarulli F; Lapolla A; Ragazzi E; Susana A; Sechi A; Nollino L; Cosma C; Fedele D; Sartore G
Atherosclerosis; 2013 Jan; 226(1):252-7. PubMed ID: 23182189
[TBL] [Abstract][Full Text] [Related]
17. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE.
Moriya S; Yamazaki M; Murakami H; Maruyama K; Uchiyama S
J Stroke Cerebrovasc Dis; 2014; 23(10):2540-2546. PubMed ID: 25282185
[TBL] [Abstract][Full Text] [Related]
18. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Nakatani Y; Ohtoshi K; Hayaishi-Okano R; Kosugi K; Hori M; Yamasaki Y
Diabetes Care; 2005 Nov; 28(11):2716-21. PubMed ID: 16249545
[TBL] [Abstract][Full Text] [Related]
19. Metabolic dysfunction in Emirati subjects in Abu Dhabi: Relationship to levels of soluble RAGEs.
Abdulle A; Inman CK; Saleh A; Noshi M; Galani D; Abdelwareth L; Alsafar H; Elfatih A; Al Shamsi H; Ali R; Li H; Ramasamy R; Schmidt AM; Benbarka MM; Hassan MH
J Clin Transl Endocrinol; 2019 Jun; 16():100192. PubMed ID: 31080742
[TBL] [Abstract][Full Text] [Related]
20. Association between endogenous secretory receptor for advanced glycation-end products (esRAGE) and carotid intima-media thickness in type 2 diabetes.
Lin X; Chen X; Ye J; Li Q; Zhou J; Wu X; Huang Y; Li X; Shi Y; Li S; Li L; Cai H
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):277-80. PubMed ID: 24839222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
